AI health platform Qura has raised €1.5m in pre-seed funding to support its plans to improve how non-emergency health conditions are managed across Europe.
The funding will be used to expand hiring across medical, engineering and operations teams, invest in digital marketing and community-led growth, advance Qura’s AI health intelligence capabilities and prepare for expansion into additional European markets.
The pre-seed funding round was led by United Ventures, with participation from Vento, Italian Angels for Growth and several angel investors.
Virginia Gambardella, chief executive and founder of Qura, said: “Millions of people know something is off, but the current system doesn’t give them the tools or the guidance to act.
“Qura changes that.
“We combine the precision of AI with the trust of a real doctor to help people stay well, not just get better.”
Qura members complete comprehensive blood testing through partner laboratories, followed by AI-driven analysis and a 45-minute consultation with a dedicated physician.
Each user then receives a personalised health plan outlining immediate actions and longer-term monitoring, supported by ongoing follow-up and medical guidance.
The company says its hybrid care model keeps physicians at the centre while artificial intelligence supports efficiency and personalisation.
An estimated one in five adults experiences persistent subclinical symptoms.
These include issues such as chronic fatigue, hormonal imbalances, digestive problems or unexplained hair loss that do not qualify as acute illness but can still affect daily life.
Traditional primary care is often not structured to manage these conditions.
Consultations may be brief, diagnostic testing can be limited and patients frequently move between specialists without a coordinated care plan.
Qura is also developing what it describes as an EU-native platform designed to be GDPR-compliant, medically validated and integrated with local laboratory networks.
